Biofourmis
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | SGD100k | Angel | |
$1.0m | Angel | ||
N/A | N/A | Early VC | |
$500k | Seed | ||
$5.0m | Series A | ||
N/A | $2.0m | Series A | |
$35.0m | Series B | ||
$100m Valuation: $700m | Series C | ||
* | $300m Valuation: $1.3b | Series D | |
* | $20.0m Valuation: $1.5b | Series D | |
Total Funding | $464m |
Recent News about Biofourmis
EditBiofourmis is a digital health company that leverages advanced technology to provide hospital-level care in the comfort of patients' homes. The company serves healthcare providers, pharmaceutical companies, and patients by offering a predictive health platform that uses biosensors and deep learning algorithms to monitor and analyze patient data. Operating in the healthcare technology market, Biofourmis' business model revolves around selling its platform and services to hospitals and healthcare systems, as well as partnering with pharmaceutical companies to enhance drug efficacy and patient outcomes. The company generates revenue through subscription fees, service contracts, and partnerships. By focusing on predictive analytics and personalized care, Biofourmis aims to prevent costly medical events and improve patient outcomes.
Keywords: predictive analytics, digital health, biosensors, deep learning, hospital-at-home, personalized care, healthcare technology, remote monitoring, patient outcomes, pharmaceutical partnerships.